© 2021 MJH Life Sciences and Center for Biosimilars®. All rights reserved.
© 2021 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
March 04, 2021
Investigators evaluated trial spending and reasons for biologics license application failures.
March 03, 2021
March 02, 2021
March 01, 2021
March 1st 2021
Robidoux's reelection comes as biosimilars get a lift from automatic switching policies in British Columbia and Alberta.
February 28th 2021
Anar Dossa, director of Pharmacy Services at Pacific Blue Cross, discusses the company's involvement with British Columbia's biosimilars switching program.
February 27th 2021
By Sarfaraz K. Niazi, PhD
Biosimilars have come a long way, and their path has mirrored that of generics—fraught with obstacles. Still, a stronger embrace is needed from physicians and payers.
February 26th 2021
By Deana Ferreri, PhD
In a review of trastuzumab treatment options, reviewers concluded subcutaneous (SC) vs intravenous (IV) options may be more costly and sometimes less practical.
Here are the top 5 biosimilar articles for the week of February 22, 2021.
February 25th 2021
By Tony Hagen
Sales of the pegfilgrastim oncology support biosimilar Udenyca fell off in late 2020, but Coherus doesn't see orginator company Amgen's advantage lasting much longer.
February 24th 2021
The Germany-based company with global operations plans to ramp up its biosimilars portfolio through 2025.
February 23rd 2021
Although a more costly medicine, obinutuzumab proved more cost-effective over the long run than rituximab biosimilars in follicular lymphoma.
February 22nd 2021
Gary H. Lyman, MD, PhD, provides an expert overview on overcoming the challenges of discussing biosimilars with patients.
February 21st 2021
We sat down with Sarfaraz Niazi, PhD, an adjunct professor and biosimilar industry expert, to discuss the potential impact high-concentration adalimumab products could have on the US market.